Carrier-based dry powder formulation for nasal delivery of vaccines utilizing BSA as model drug

Trows, Sabrina; Scherließ, Regina

doi:10.1016/j.powtec.2016.01.042

Cited by 35 publications

(17 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thin-film freeze-drying was also reported as a method to successfully convert liquid vaccines containing aluminum salts to DPVs [72]. A more recent approach instead is based on the encapsulation of the vaccine components in mucoadhesive particles, and then the particles are converted into a dry powder [73–76].…”

Section: Dry Powder Vaccines Tested In Vivomentioning

confidence: 99%

Intranasal immunization with dry powder vaccines

Bahamondez-Canas

Cui

2018

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

Vaccination represents a cost-effective weapon for disease prevention and has proven to dramatically reduce the incidences of several diseases that once were responsible for significant mortality and morbidity worldwide. The nasal cavity constitutes the initial stage of the respiratory system and the first contact with inhaled pathogens. The intranasal (IN) route for vaccine administration is an attractive alternative to injection, due to the ease of administration as well as better patient compliance. Many published studies have demonstrated the safety and effectiveness of IN immunization with liquid vaccines. Currently, two liquid IN vaccines are available and both contain live attenuated influenza viruses. FluMist® was approved in 2003 in the United States, and Nasovac® H1N1 vaccine was approved in India in 2010. Preclinical studies showed that IN immunization with dry powder vaccines (DPVs) is feasible. Although there is not a commercially available DPV yet, DPVs have the inherent advantage of being relatively more stable than liquid vaccines. This review focuses on recent developments of DPVs as next-generation IN vaccines.

show abstract

Section: Dry Powder Vaccines Tested In Vivomentioning

confidence: 99%

Intranasal immunization with dry powder vaccines

Bahamondez-Canas

Cui

2018

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

show abstract

“…Accordingly, the nose can be a great alternative administration route in the therapy of CNS diseases or when the target is in the CNS (e.g., brain tumors). Thus, in recent years, researchers have made some efforts to formulate drug delivery systems for the treatment of schizophrenia [11,12], epilepsy [13,14], Alzheimer's disease [15][16][17][18], Parkinson's disease [19,20], migraine [21], vaccination [22,23], and brain tumor [24]. In some cases the aim was to formulate nanosystems, that may be advantageous due to reduced particle size and increased particle surface, which can affect the absorption positively [25].…”

Section: Introductionmentioning

confidence: 99%

Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity

et al. 2020

View full text Add to dashboard Cite

Nasal drug delivery has become a popular research field in the last years. This is not surprising since the nose possesses unique anatomical and physical properties. Via the nasal mucosa local, systemic, and directly central nerve systemic (CNS) effect is achievable. Powders have favorable physicochemical properties over liquid formulations. Lamotrigine (LAM) is an antiepileptic agent with a relatively mild side effect spectrum, but only available in tablet form on market. Reducing the particle size to the nano range can affect the bioavailability of pharmaceutical products. The aim of this article was to continue the work started, compare the in vitro properties of a nanonized lamotrigine containing nasal powder (nanoLAMpowder) and its physical mixture (PM) that were prepared by dry milling. Moreover, to study their trans-epithelial absorption to reach the blood and target the brain by axonal transport. Due to the dry milling technique, the particle size of LAM, their surface and also their structure changed that led to higher in vitro dissolution and permeability rate. The results of the in vivo tests showed that the axonal transport of the drug was assumable by both intranasal formulations because the drug was present in the brain within a really short time, but the LAM from the nanoLAMpowder liberated even faster.

show abstract

“…As a result, preservatives are not needed and also the unexpected incompatibilities are not common. Their shelf life is longer and the transport is much easier, but packaging must ensure protection against humidity and light [8][9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%